Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Amneal Pharmaceuticals, Inc. < Previous 1 2 Next > Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose April 24, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine April 16, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Report First Quarter 2024 Results on May 3, 2024 April 10, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 March 28, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension March 25, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Reports Fourth Quarter and Full Year 2023 Financial Results March 01, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203 February 27, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Participate at Upcoming Investor Conference February 13, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024 January 31, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension January 10, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023 January 04, 2024 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference December 21, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Announces Move to Nasdaq December 15, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone) December 07, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules December 01, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Reports Third Quarter 2023 Financial Results November 07, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Participate at Upcoming Investor Conferences November 03, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance October 23, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio October 12, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Report Third Quarter 2023 Results on November 7, 2023 October 05, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection September 06, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Receives First Product Approval in China September 06, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate September 06, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India August 29, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Participate at the 2023 Wells Fargo Healthcare Conference August 25, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease August 24, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Reports Second Quarter 2023 Financial Results August 04, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics July 26, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal to Report Second Quarter 2023 Results on August 4, 2023 July 06, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter July 03, 2023 From Amneal Pharmaceuticals, Inc. Via Business Wire Tickers AMRX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.